Simaravibart Biosimilar – Anti-SARS-CoV-2 RBD mAb – Research Grade

Introduction

Simaravibart Biosimilar – Anti-SARS-CoV-2 RBD mAb – Research Grade is a novel monoclonal antibody (mAb) developed as a potential therapeutic agent against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This biosimilar product is a result of extensive research and development efforts in the field of antibody therapeutics, with the aim of providing a safe and effective treatment option for individuals infected with the SARS-CoV-2 virus.

Structure of Simaravibart Biosimilar

Simaravibart Biosimilar is a recombinant humanized mAb that specifically targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The mAb is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable regions are responsible for binding to the RBD of the virus, while the constant regions provide stability and effector functions.

Mechanism of Action

Simaravibart Biosimilar works by binding to the RBD of the SARS-CoV-2 virus, preventing it from attaching to and infecting host cells. This inhibits the virus from entering and replicating within the cells, thereby reducing the viral load and slowing down the progression of the disease. Additionally, the mAb also triggers an immune response by activating the complement system and recruiting immune cells to further eliminate the virus.

Research Grade

Simaravibart Biosimilar is currently in the research grade stage, which means it is being developed and tested in preclinical and clinical studies. This stage is crucial in determining the safety, efficacy, and optimal dosage of the mAb. The biosimilar is being evaluated in various animal models and human clinical trials to assess its therapeutic potential and to gather data on its pharmacokinetics, pharmacodynamics, and adverse effects.

Therapeutic Target

The therapeutic target of Simaravibart Biosimilar is the SARS-CoV-2 virus, specifically the RBD of its spike protein. The RBD is a key component of the virus that is responsible for binding to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells, facilitating viral entry and infection. By targeting the RBD, Simaravibart Biosimilar aims to block this interaction and prevent the virus from causing further damage.

Potential Applications

Simaravibart Biosimilar has the potential to be used as a treatment option for individuals infected with SARS-CoV-2. It can also be used as a prophylactic agent for individuals at high risk of exposure to the virus, such as healthcare workers and close contacts of infected individuals. Furthermore, the mAb may also have a role in post-exposure prophylaxis to prevent the progression of the disease in individuals who have been exposed to the virus.

Conclusion

In conclusion, Simaravibart Biosimilar – Anti-SARS-CoV-2 RBD mAb – Research Grade is a promising therapeutic candidate for the treatment of COVID-19. Its unique mechanism of action and specific targeting of the RBD make it a potentially effective and safe option for individuals infected with the SARS-CoV-2 virus. As research and development efforts continue, Simaravibart Biosimilar may play a crucial role in mitigating the impact of the ongoing COVID-19 pandemic.

ProteoGenix catalogue number PX-TA1935. For research use only.

Target: Simaravibart Biosimilar – Anti-SARS-CoV-2 RBD mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: 0.01M PBS, pH 7.4; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet